Research and Markets: Triple Analysis: Breast Cancer, Colorectal Cancer and Angiogenesis - Now Available

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/9fde57/triple_analysis_b) has announced the addition of the "Triple Analysis: Breast Cancer, Colorectal Cancer and Angiogenesis" report to their offering.

This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Colorectal Cancer and by the mechanism/target/effect of Angiogenesis. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Breast Cancer The breast cancer report part comprises defined and up to date development strategies for 405 breast cancer drugs within the portfolio of 220 investigators, from Ceased to Marketed. This report part extensively analyses 207 identified targets of breast cancer drugs, organized into 193 drug target strategies, and assesses them in breast cancer. This part is based on the following publication: Portfolio Analytics and Planning in the Breast Cancer Pipeline - Change is Around the Corner in a Highly Competitive Market Place

Part II: Colorectal Cancer The colorectal cancer report part comprises defined and up to date development strategies for 156 colorectal cancer drugs within the portfolio of 108 investigators, from Preclinical to Marketed. This report part extensively analyses 120 identified targets of colorectal cancer drugs, organized into 105 drug target strategies, and assesses them in colorectal cancer. This part is based on the following publication: Currently Druggable in Colorectal Cancer: A Drug Target Competitive Analysis

Part III: Angiogenesis The angiogenesis report part comprises defined and up to date development strategies for 123 anti-angiogenesis drugs in oncology within the portfolio of 90 investigators, from Preclinical to Marketed. This report part extensively analyses 108 identified targets of angiogenesis drugs, organized into 88 drug target strategies, and assesses them in 44 different cancer indications This part is based on the following publication: Target Atlas: Competitive Insights to Anti-Angiogenic Drug R&D in Oncology

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies pipeline and portfolio planning (PPP) in cancer by:

  • Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
  • Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drugs properties
  • Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
  • Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities
  • Supporting development of integrative molecule, pathway and disease area strategies
  • Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Breast Cancer

Part II: Colorectal Cancer

Part III: Angiogenesis

For more information and a full TOC please visit http://www.researchandmarkets.com/research/9fde57/triple_analysis_b



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:

INDUSTRY KEYWORDS:   Health  Oncology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.